2021

January 31, 2022

Second Supply Agreement for Anagenics’ FGF5 Inhibitors

December 16, 2021

Change of Company Name

December 15, 2021

Annual General Meeting – CEO Presentation

December 15, 2021

Release of Shares from Voluntary Escrow

December 15, 2021

Results of Annual General Meeting

November 11, 2021

Cellmid receives R&D tax credit

November 10, 2021

Proposed issue of securities – CDY

November 10, 2021

Letter to Shareholders – Notice of Annual General Meeting

November 10, 2021

Notice of Annual General Meeting – Proxy Form